Keywords: BTK; ABC; activated B-cell type; BCM; BCL10, CARD11, MALT complex; BCR; B-cell receptor; BTK; Bruton's tyrosine kinase; CSF; cerebrospinal fluid; GCB; germinal center B-cell type; IL; interleukin; PCNSL; primary central nervous system lymphoma; TLR; toll-lik
مقالات ISI BTK (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: BTK; Urticaria; Biomarkers; CRP; IL-6; MPV; D-dimer; F1+2; Biologics; Omalizumab; ASCENT-I; ASCENT-II; GLACIAL; IL-1 antagonists; TNF-α inhibitors; Intravenous immunoglobulin; Rituximab; Ligelizumab; Quilizumab; ASST; Autologous serum skin test; ATA; Antithyr
Keywords: BTK; Resistin-like molecule; Macrophage; Helminth infection; T helper type 2; Toll-like Receptor 4; ABC; ATP-binding cassette transporter; ADD1; adipocyte determination and differentiation dependent factor 1; ADSF; adipocyte secreted factor; Akt (aka PKB); pro
Keywords: BTK; ABC; activated-B Cell; BTK; Bruton's tyrosine kinase; CNS; Central nervous system; CLL; chronic lymphocytic leukemia; DLBCL; Diffuse Large B-cell lymphoma; DAB; diaminobenzidin; DNMT; DNA methyltransferase; GO; gene ontology; GCB; germinal center cell lik
Keywords: BTK; Flow cytometry; Intracellular protein; Monoclonal antibody; Primary immunodeficiency disease; Surface protein; ADA; adenosine deaminase; ALPS; autoimmune lymphoproliferative syndrome; APECED; autoimmune polyendocrinopathy-candidiasis-ectodermal dystrop
Keywords: BTK; ADA; anti-drug antibodies; AMPK; 5â² adenosine monophosphate-activated protein kinase; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; APC; antigen presenting cells; AT; anaphylatoxin; BTK; Bruton's tyrosine kinase; C1q
Keywords: BTK; AIHA; autoimmune hemolytic anemia; B2M; β2-microglobulin; BR; bendamustine and rituximab; BTK; Bruton tyrosine kinase; CLL; chronic lymphocytic leukemia; CR; complete remission; FCR; fludarabine; cyclophosphamide; and rituximab; FISH; fluorescence in sit
Keywords: BTK; 5-FU; 5-fluorouracil; AF; atrial fibrillation; ALK; anaplastic lymphoma kinase; APD; action potential duration; APL; acute promyelocytic leukemia; BCR-ABL; breakpoint cluster region-Abelson; BTK; Bruton tyrosine kinase; CD20; cluster of differentiation 20
Keywords: BTK; AS; area stenosis; BTK; below-the-knee; CLI; critical limb ischemia; DPU; Doppler perfusion units; FFR; fractional flow reserve; stress FFRperiph; Peripheral fractional flow reserve; LL; lesion length; MLD; minimum lumen diameter; PTA; percutaneous transl
Keywords: BTK; BTK; Bruton tyrosine kinase; PTK2; protein tyrosine kinase 2; TSPAN7; tetraspanin 7; CTSD; cathepsin; MEF2C; myocyte enhancer factor 2C; TCF3; transcription factor 3; FES; Feline sarcoma; RPL36A; ribosomal protein L36a; NCF4; neutrophil cytosolic factor 4
Keywords: BTK; DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NHL; non-Hodgkin lymphoma; GEP; gene expression profiling; COO; cell-of-origin; GCB; germinal center B-cell; ABC; activated B-cell; PMBL;
Keywords: BTK; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: BTK; ASH; American Society of Hematology; ATAP; amphipathic tail-anchoring peptide; BAD; BCL-2-associated death promoter protein; BAK; BCL-2 homologous antagonist killer; BAX; BCL-2-associated X protein; BCL-2; B-cell lymphoma 2; BCL-w (BCL2L2); BCL-2-like pro
Keywords: BTK; ADCC; antibody-dependent cell-mediated cytotoxicity; ASC; antibody secreting cell; AHR; airway hyperresponsiveness; βc; common β; BCGF; B cell growth factor; BCDF; B cell differentiation factor; BCL1; murine chronic B leukemia; Btk; Bruton's tyrosine
Keywords: BTK; ATK; above-the-knee; ALI; acute limb ischemia; BTK; below-the-knee; TIMI; Thrombolysis in Myocardial Infarction; VAT; vacuum-assisted thrombectomy;
Keywords: BTK; Hairy cell leukemia; HCL; Microenvironment; B cell receptor; BCR; BTK; Ibrutinib;
Keywords: BTK; Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: BTK; BTK; Bruton tyrosine kinase; CGD; chronic granulomatous disease; CMC; chronic mucocutaneous candidiasis; γc; γ-common; HLH; hemophagocytic lymphohistiocytosis; HSCT; hematopoietic stem cell transplantation; ITK; IL2-inducible T cell kinase; NK; natural
Keywords: BTK; S/B; signal to background; PDGFR; platelet-derived growth factor receptor; BTK; Bruton's tyrosine kinase; EGFR; epidermal growth factor receptor; HER-2; human epidermal growth factor 2; AMPK; AMP activated protein kinase; BMPR; bone morphogenetic protei
Keywords: BTK; AP-1; activator protein-1; BLNK; B cell linker protein; BTK; Bruton's tyrosine kinase; CCT; choline cytidylyltransferase; CDP-choline; cytidine diphosphocholine; CEPT1; choline/ethanolamine phosphotransferase 1; Cer; ceramide; CK; choline kinase; CPT1; ch
Keywords: BTK; Immunology; primary immunodeficiency; nuclear factor κB; autoimmunity; intravenous immunoglobulin; common variable immunodeficiency; severe combined immunodeficiency; newborn screening; gene therapy; ADA; Adenosine deaminase; ADAM; A disintegrin and meta
Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series
Keywords: BTK; Bruton's tyrosine kinase; BTK; Indole carboxamide; Carbazole; Irreversible inhibitor;
Transforming growth factor-β1 impairs lymph node homing of dendritic cells by downregulating C-type lectin receptor-2 expression
Keywords: BTK; c-Src; C-type lectin receptor; Dendritic cell trafficking; Immunosuppressive cytokines; BMDC; bone marrow-derived dendritic cell; Btk; Bruton's tyrosine kinase; CLEC-2; C-type lectin receptor-2; DC; dendritic cell; GM-CSF; granulocyte-macrophage colony-
Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ
Keywords: BTK; Benzofuro[3,2-b]pyridin-2(1H)-one; Synthesis; Leukemia; Btk; PI3K;
Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry
Keywords: BTK; BTK; Bruton's tyrosine kinase; CGS; cysteinylglycine dipeptide; CYS; cysteine (amino acid); DHI; dihydrodiol-ibrutinib; DHP-I; dihydropeptidase-I; DMSO; dimethyl sulfoxide; GLU; glutamate (amino acid); GSH; glutathione tripeptide; GST; glutathione-S-trans
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4
Keywords: BTK; ABC; Activated B Cell-like; BTK; Bruton's Tyrosine Kinase; CD79; Cluster of Differentiation 79; CDK; Cyclin Dependent Kinase; CLK; CDC-Like Kinase; DCM; dichloromethane; DDQ; 2,3-Dichloro-5,6-DicyanobenzoQuinone; DIPEA; N,N-diisopropylethylamine; DLBCL;
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia
Keywords: BTK; Waldenström macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors;
The spatial molecular pattern of integrin recognition sites and their immobilization to colloidal nanobeads determine α2β1 integrin-dependent platelet activation
Keywords: BTK; Platelet signaling; Platelet activation; Integrin α2β1 cluster; Nanopatterning; Biofunctionalized nanobeads and nano-sized membrane protein clusters; BCECF-AM; 2â²,7â²-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein-acetoxymethyl ester; BSA; bovine
The Bylock fallacy: An In-depth Analysis of the Bylock Investigations in Turkey
Keywords: BTK; Bylock; Turkish IT law; Data retention; Data protection; Turkish criminal procedural code; Turkish penal code; The Gülen movement; Evidence; Digital data; Digital forensics; MIT; BTK; Manipulation of data;
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma
Keywords: BTK; B-cell receptor signaling; BTK; PI3K; PCNSL; DLBCL;
Molecular characterization and function analysis of grouper (Epinephelus coioides) Bruton's tyrosine kinase BTK
Keywords: BTK; Epinephelus coioides; Cryptocaryon irritans; BTK; Ibrutinib;
FOXOs in cancer immunity: Knowns and unknowns
Keywords: BTK; 2B4; CD244 molecule; AKT or PKB; protein kinase B; APCs; antigen-presenting cells; ARG1; arginase 1; BEC; blood endothelial cell; BLNK; B cell Linker protein; BMP; bone morphogenetic protein; BTK; Bruton tyrosine kinase; C/EBP; CCAAT/enhancer-binding prot
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis
Keywords: BTK; Btk; Inhibitor; Selectivity; Bioavailability; Aqueous solubility; Rheumatoid arthritis;
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Keywords: BTK; Akt; oncogene in the transforming retrovirus, AKT8; AP-1; activator protein 1; ARAF; v-raf murine sarcoma 3611 viral oncogene homologue; ASK1; apoptosis signal-regulating kinase 1; BCL2; B-cell lymphoma 2; BCL-XL; B-cell lymphoma extra large; BRAF; v-raf
Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK)
Keywords: BTK; Bruton's tyrosine kinase; BTK; Reactive metabolite; Covalent binding; Glutathione adduct;
Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency
Keywords: BTK; BCR; B-cell receptor; Btk; Bruton's tyrosine kinase; CD40L; CD40 ligand; CVID; Common variable immunodeficiency; Erk; extracellular signal-related kinase; IκBα; NFκB inhibitor α; Ig; immunoglobulin; IVIG; intravenous immunoglobulin; PCA; principle com
Wound Blush Obtainment Is the Most Important Angiographic Endpoint for Wound Healing
Keywords: BTK; critical limb ischemia; endovascular therapy; wound healing; BTA; below the ankle; BTK; below the knee; CLI; critical limb ischemia; EVT; endovascular therapy; SPP; skin perfusion pressure; WB; wound blush;
Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway
Keywords: BTK; BM-MSCs; Bone marrow mesenchymal stem cells; MM; multiple myeloma; BTK; Bruton tyrosine kinase; MMSCs; multiple myeloma stem cells; OS; overall survival; PFS; progression-free survival; Bone marrow mesenchymal stem cells; Stemness; Bruton tyrosine kinase;
A pleckstrin homology-like domain is critical for F-actin binding and cofilin-phosphatase activity of Slingshot-1
Keywords: BTK; Slingshot; Cofilin; Pleckstrin homology (PH) domain; Actin binding; Phosphatase; Btk; Bruton's tyrosine kinase; CD; circular dichroism; CFP; cyan fluorescent protein; Itk; interleukin-2-inducible T-cell tyrosine kinase; LHK motif; Leu-His-Lys motif; OSBP;
Long-Term Primary Patency Rate After Nitinol Self-Expandable Stents Implantation in Long, Totally Occluded Femoropopliteal (TASC II C & D) Lesions
Keywords: BTK; TASC; Trans-Atlantic Inter-Society Consensus; PTA; Percutaneous transluminal balloon angioplasty; PAD; Peripheral arterial disease; CLI; Critical limb ischaemia; CAD; Coronary artery disease; TIA; Transient ischaemic attack; ABI; Ankle/Brachial Index; CFA
Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines
Keywords: BTK; Leukemia; BTK; DPPY; Phosphoryl; Inhibitor;
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: AÂ Single-center Experience
Keywords: BTK; Atrial fibrillation; Bleeding; BTK; Immunoglobulins; Peripheral lymphocytosis;
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
Keywords: BTK; Leukemia; BTK; Inhibitor; Pyrimidine; Sulfonamide;
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance
Keywords: BTK; FDA; US Food and Drug Administration; EGFR; epidermal growth factor receptor; BTK; Bruton's tyrosine kinase; SPR; surface plasmon resonance; PI3K; phosphoinositide 3-kinase; SD; standard deviation; SE; standard error; PI3K; phosphoinositide 3-kinase; SPR;
Terminal 14q32.33 deletion as a novel cause of agammaglobulinemia
Keywords: BTK; XLA; X-linked agammaglobulinemia; BTK; Bruton's tyrosine kinase; IGHC; Immunoglobulin heavy chain gene locus; SCID; Severe combined immunodeficiency syndrome; BCR; B-cell receptor; VDJ; Variable, diversity and joining gene segments; IGHM; Immunoglobulin h
Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis
Keywords: BTK; BTK; Reversible; 1H-Pyrrolo[2,3-b]pyridine; Human whole blood; Kinase selectivity; Autoimmune diseases; Rheumatoid arthritis;
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior
Keywords: BTK; ADME; absorption distribution metabolism excretion; BODIPY; borondipyrromethene; BTK; Bruton's tyrosine kinase; CIW; cranial imaging window; DCE-MRI; dynamic contrast enhanced magnetic resonance imaging; DiO/DiI/DiD/DiR; dialkylcarbocyanine dyes; ECM; e
Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines
Keywords: BTK; Leukemia; BTK; Pyrimidine; Synthesis; Inhibitor;
Local Ultrasound to Enhance Paclitaxel Delivery After Femoral-Popliteal Treatment in Critical Limb Ischemia
Keywords: BTK; critical limb ischemia; femoral-popliteal artery disease; paclitaxel; ultrasound; BTK; below-the-knee; CLI; critical limb ischemia; DEB; drug-eluting balloon; DSA; digital subtraction angiography; DUS; duplex ultrasonography; FU; follow-up; MI; myocardial
Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton’s tyrosine kinase inhibitors
Keywords: BTK; BTK; Covalent kinase inhibitor; Pyrimidine; Structure–activity relationship; Molecular dynamics simulation